Pozzi Marco, Conti Valentino, Locatelli Federica, Galbiati Sara, Radice Sonia, Clementi Emilio, Strazzer Sandra
Scientific Institute IRCCS Eugenio Medea, Lecco, Italy (Drs Pozzi, Locatelli, Galbiati, Clementi, and Strazzer); Regional Centre for Pharmacovigilance of Lombardy, Milan, Italy (Dr Conti); Unit of Clinical Pharmacology, Department of Biomedical and Clinical Sciences L. Sacco, "Luigi Sacco" University Hospital, Università di Milano, Milan, Italy (Dr Radice); and Unit of Clinical Pharmacology, CNR Institute of Neuroscience, Department of Biomedical and Clinical Sciences L. Sacco, "Luigi Sacco" University Hospital, Università di Milano, Milan, Italy (Dr Clementi).
J Head Trauma Rehabil. 2017 Mar/Apr;32(2):117-124. doi: 10.1097/HTR.0000000000000255.
Information on course and treatment of paroxysmal sympathetic hyperactivity (PSH) during rehabilitation and in pediatric patients is lacking. To increase knowledge on the course and treatment of PSH in pediatric patients during rehabilitation, we retrospectively analyzed 23 pediatric patients with PSH, describing the course of PSH and administered drugs, and explored the association of PSH remission with drug doses.
Neurorehabilitation unit of IRCCS Eugenio Medea, Bosisio Parini (LC), Italy.
Twenty-three pediatric patients with postacute acquired brain injury, who remitted from PSH.
Retrospective cohort study.
Description of features and course of PSH, description of drug therapies, and analysis of covariance of their doses. Correlations between remission and drug doses/clinical variables. Estimation of the odds ratios of remission.
At admittance patients displayed at least 3 features of PSH with an overall score of 9, which diminished progressively during remission. Therapies with propranolol, baclofen, niaprazine, and diazepam were progressively uptitrated, indicating potential usefulness. When testing possible predictors of remission, we found positive effects of propranolol and diazepam and of traumatic etiology and a negative effect of maximum PSH severity.
Results should be interpreted carefully regarding causal relationships and drug doses and combinations, but they encourage further studies on the use of propranolol and diazepam to favor PSH remission.
目前缺乏关于康复期间和儿科患者阵发性交感神经过度兴奋(PSH)病程及治疗的信息。为了增加对儿科康复患者PSH病程及治疗的了解,我们回顾性分析了23例患有PSH的儿科患者,描述了PSH病程及用药情况,并探讨了PSH缓解与药物剂量之间的关联。
意大利博西奥帕里尼(LC)的IRCCS欧金尼奥·美狄亚神经康复科。
23例急性获得性脑损伤后出现PSH且病情缓解的儿科患者。
回顾性队列研究。
PSH的特征和病程描述、药物治疗描述及其剂量的协方差分析。缓解与药物剂量/临床变量之间的相关性。缓解比值比的估计。
入院时患者至少表现出3项PSH特征,总分9分,在缓解过程中逐渐降低。普萘洛尔、巴氯芬、尼阿嗪和地西泮的治疗剂量逐渐增加,表明可能有效。在测试缓解的可能预测因素时,我们发现普萘洛尔和地西泮、创伤性病因有积极作用,而PSH最大严重程度有消极作用。
关于因果关系以及药物剂量和组合,应对结果进行谨慎解读,但这些结果鼓励进一步研究使用普萘洛尔和地西泮以促进PSH缓解。